Pancreatic Cancer Research

ResearcherInsermNo recent work listed

Valérie Paradis

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3142-3762; OpenAlex author ID A5055720674. Sources: ClinicalTrials.gov.

Their work

Papers
8
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 3 papers · 2020: none · 2021: 1 paper · 2022: 1 paper, 1 trial · 2023: 1 paper

Papers 8

  1. Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma. Co-author DOI 10.1038/s41467-023-39026-y↗
  2. PACpAInt: a deep learning approach to identify molecular subtypes of pancreatic adenocarcinoma on histology slides Co-author DOI 10.1101/2022.01.04.474951↗
  3. Pancreatic Ductal Adenocarcinoma Arising in Young and Old Patients Displays Similar Molecular Features. Co-author DOI 10.3390/cancers13061234↗
  4. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/path.5224↗
  5. Prognostic Biomarkers in Pancreatic Cancer: Avoiding Errata When Using the TCGA Dataset. Co-author DOI 10.3390/cancers11010126↗
  6. hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status. Co-author DOI 10.3390/cancers11111808↗
  7. In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.24084↗
  8. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis. Co-author DOI 10.1111/his.12691↗

Trials 1

  1. METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors Principal investigator NCT05794048↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jerome F. Cros · 8 shared papers, 2015–2023 · strength 0.72
  2. Rémy Nicolle · 5 shared papers, 2019–2023 · strength 0.53
  3. Pascal R. Hammel · 5 shared papers, 2015–2023 · strength 0.47
  4. Jean‐Baptiste Bachet · 5 shared papers, 2015–2023 · strength 0.47
  5. Magali Svrcek · 4 shared papers, 2019–2023 · strength 0.42
  6. Vinciane Rebours · 4 shared papers, 2018–2023 · strength 0.42
  7. Anne Couvelard Benveniste · 5 shared papers, 2015–2021 · strength 0.40
  8. Cindy Neuzillet · 4 shared papers, 2015–2023 · strength 0.36
  9. Louis de Mestier · 4 shared papers, 2015–2023 · strength 0.36
  10. Jérôme Raffenne · 3 shared papers, 2019–2021 · strength 0.28
  11. Charlie Saillard · 2 shared papers, 2022–2023 · strength 0.24
  12. Magali Richard · 2 shared papers, 2022–2023 · strength 0.24
  13. Juan Iovanna · 2 shared papers, 2022–2023 · strength 0.24
  14. Nelson Dusetti · 2 shared papers, 2022–2023 · strength 0.24
  15. Francesco Puleo · 2 shared papers, 2019–2021 · strength 0.18
  16. Annemilaï Tijeras‐Raballand · 2 shared papers, 2015–2019 · strength 0.12
  17. Philippe B Ruszniewski · 2 shared papers, 2015–2018 · strength 0.12
  18. Alain Sauvanet Sauvanet · 2 shared papers, 2015–2018 · strength 0.12
  19. Jérôme Torrisani · 1 shared paper, 2021 · strength 0.10
  20. Raphaël Maréchal · 1 shared paper, 2019 · strength 0.08
  21. Pierre Laurent‐Puig · 1 shared paper, 2019 · strength 0.08
  22. Anguraj Sadanandam · 1 shared paper, 2019 · strength 0.08
  23. Corinne Bousquet · 1 shared paper, 2019 · strength 0.08
  24. Mert Erkan · 1 shared paper, 2019 · strength 0.08
  25. Francesca Romana Delvecchio · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.